PKMYT1 is a marker of treatment response and a therapeutic target for CDK4/6 inhibitor-resistance in ER+ breast cancer

Authors

Anran Chen, Baylor College of Medicine
Cynthia X Ma, Washington University School of Medicine in St. Louis
et al.

Journal

Molecular Cancer Therapeutics

Publication Date

10-1-2024

Volume

23

Issue

10

First Page

1494

Last Page

1510

Document Type

Open Access Publication

DOI

10.1158/1535-7163.MCT-23-0564

Rights and Permissions

Chen A, Kim BJ, Mitra A, Vollert CT, Lei JT, Fandino D, Anurag M, Holt MV, Gou X, Pilcher JB, Goetz MP, Northfelt DW, Hilsenbeck SG, Marshall CG, Hyer ML, Papp R, Yin SY, De Angelis C, Schiff R, Fuqua SAW, Ma CX, Foulds CE, Ellis MJ. PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 1;23(10):1494-1510. doi: 10.1158/1535-7163.MCT-23-0564 This open access article is distributed under the Creative Commons Attribution NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. ©2024 The Authors; Published by the American Association for Cancer Research

Recommended Citation

Chen, Anran; Ma, Cynthia X; and et al., "PKMYT1 is a marker of treatment response and a therapeutic target for CDK4/6 inhibitor-resistance in ER+ breast cancer." Molecular Cancer Therapeutics. 23, 10. 1494 - 1510. (2024).
https://digitalcommons.wustl.edu/oa_4/4200

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.